TY - JOUR
T1 - Expression profile of class I histone deacetylases in human cancer tissues
AU - Nakagawa, Masamune
AU - Oda, Yoshinao
AU - Eguchi, Takashi
AU - Aishima, Shin Ichi
AU - Yao, Takashi
AU - Hosoi, Fumihito
AU - Basaki, Yuji
AU - Ono, Mayumi
AU - Kuwano, Michihiko
AU - Tanaka, Masao
AU - Tsuneyoshi, Masazumi
PY - 2007/10
Y1 - 2007/10
N2 - Histone deacetylase (HDAC) activity is one of the widely used and well-established mechanisms for regulation of various genes in cancer. To identify which subtype of class I HDACs are overexpressed in cancers, we analyzed the expression of class I HDAC isotypes composed of HDAC1, 2, 3 and 8 in several cell lines and human cancer tissues, including cancer of the stomach, esophagus, colon, prostate, breast, ovary, lung, pancreas and thyroid. The results showed that >75% of human cancer tissues and their corresponding non-cancerous epithelium showed high expression of these class I HDACs. However, the immunoreactivity of HDAC8 in both prostatic cancer tissue and non-cancerous prostate glands was lower than that in other cancer tissues. Furthermore, 5-40% of cancer tissues overexpressed class I HDACs, when compared with normal epithelium. The results suggest the potential usefulness of HDAC inhibitors for the treatment of a wide variety of human cancers.
AB - Histone deacetylase (HDAC) activity is one of the widely used and well-established mechanisms for regulation of various genes in cancer. To identify which subtype of class I HDACs are overexpressed in cancers, we analyzed the expression of class I HDAC isotypes composed of HDAC1, 2, 3 and 8 in several cell lines and human cancer tissues, including cancer of the stomach, esophagus, colon, prostate, breast, ovary, lung, pancreas and thyroid. The results showed that >75% of human cancer tissues and their corresponding non-cancerous epithelium showed high expression of these class I HDACs. However, the immunoreactivity of HDAC8 in both prostatic cancer tissue and non-cancerous prostate glands was lower than that in other cancer tissues. Furthermore, 5-40% of cancer tissues overexpressed class I HDACs, when compared with normal epithelium. The results suggest the potential usefulness of HDAC inhibitors for the treatment of a wide variety of human cancers.
UR - http://www.scopus.com/inward/record.url?scp=38449100788&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38449100788&partnerID=8YFLogxK
U2 - 10.3892/or.18.4.769
DO - 10.3892/or.18.4.769
M3 - Article
C2 - 17786334
AN - SCOPUS:38449100788
VL - 18
SP - 769
EP - 774
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 4
ER -
